We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Improved Molecular Backbone Enhances Function of RNA Interference Tools

By LabMedica International staff writers
Posted on 31 Dec 2013
Biotechnology researchers have reported significant progress in the development of synthetic RNAi (RNA interference) tools by enhancing the efficiency of the molecule's 30-nucleotide backbone.

Investigators at Mirimus Inc. More...
(Cold Spring Harbor, NY, USA) have been working to improve short hairpin RNA (shRNA) technology to better enable stable and regulated gene repression.

A short hairpin RNA (shRNA) is a snippet of RNA that contains a structural tight hairpin turn and that can be used to silence gene expression via RNA interference. The shRNA hairpin structure is cleaved by the cellular machinery into siRNA (short interfering RNA), which is then bound to the RNA-induced silencing complex (RISC). This complex knocks out gene expressing by binding to and cleaving mRNAs, which match the siRNA that is bound to it.

However, due to incomplete understanding of natural microRNA synthesis, artificial shRNAs often fail to trigger potent gene knockdown, especially when expressed from a single genomic copy. The investigators reported in the December 12, 2013, online edition of the journal Cell Reports that they had identified a conserved element 3′ of the basal stem as critically required for optimal shRNA processing and incorporated it into an optimized backbone that they called “miR-E,” which strongly increased mature shRNA levels and knockdown efficacy.

The investigators stated that existing miR-30 reagents could easily be converted to miR-E, and its combination with up-to-date design rules established a validated and accessible platform for generating effective single-copy shRNA libraries.

First author Dr. Christof Fellmann, senior researcher at Mirimus, said, "The molecular underpinnings of efficient gene silencing are yet to be fully understood. Potent RNAi triggers are rare and have to be identified among hundreds to thousands of possibilities for each gene. To advance current techniques, we looked at the evolutionary conservation of natural RNAi triggers to build enhanced synthetic analogues. This advancement is highly relevant to reduce to practice the great promise of RNAi for drug discovery and biomedical research."

Related Links:
Mirimus Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.